Abstract: Described herein are systems and methods for generating a product enriched in one or more target particles, comprising a cassette to which the one or more microfluidic cartridges are releasably coupled and supported, the cassette comprising (i) a plurality input containers releasably and fluidically coupled thereto, wherein at least one of the plurality of input containers comprises an incoming sample, (ii) a plurality of outlets having a plurality of output containers releasably and fluidically coupled thereto, (iii) one or more microfluidic cartridges for separating one or more target particles from the sample, and (iv) a plurality of fluidic channels extending between the plurality of inlets, the plurality of outlets, and the one or more microfluidic cartridges, wherein the cassette having the plurality of input containers, the plurality of output containers, and the one or more microfluidic cartridges coupled thereto, collectively provides a closed end-to-end sterile environment that enables inline contin

Abstract: An antibody, antigen binding fragment thereof and compositions comprising the same, which is an inhibitor of signalling through IL-13R?1, by binding the said receptor, for use in the treatment of allergic disease, such as atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) in a highly allergic patient where the baseline IgE levels have been established and are at a level of at least 10,000 KU/L+/?2,000.

Abstract: An antibody, antigen binding fragment thereof or a pharmaceutical formulation, which is an inhibitor of signalling through IL-13R?1 by binding said receptor and compositions comprising the same for use in the treatment of atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) by parenteral administration of a treatment cycle comprising a dose in the range 200 mg to 600 mg, (such as 400 to 600 mg), wherein the disease is modified by a percentage reduction in EASI score in the range ?20 to ?100% from the baseline.

Abstract: The present disclosure provides a method of treatment comprising inhibiting IL-13R with an antibody or binding fragment thereof specific for the receptor with a VH sequence of SEQ ID NO: 51 or a sequence at least 95% identical thereto, and VL sequence of SEQ ID NO: 53 or a sequence at least 95% identical thereto, wherein said antibody or binding fragment is administered at a dose in the range 600 mg to 900 mg at least once each month, in particular less than twice a month.

Abstract: The invention provides a method for the purification of cytochrome P450 molecules, the method comprising expressing in a host cell culture a cytochrome P450 molecule; recovering said cells from said culture and suspending said cells in a high salt buffer; lysing said cells and removing cell debris to provide a high-salt lysate; adding to said lysate a detergent to provide a high-salt-detergent lysate; and recovering said P450 from said lysate. The method provides yields of P450 proteins suitable for crystallization.

Abstract: The invention provides a method for the purification of cytochrome P450 molecules, the method comprising expressing in a host cell culture a cytochrome P450 molecule; recovering said cells from said culture and suspending said cells in a high salt buffer; lysing said cells and removing cell debris to provide a high-salt lysate; adding to said lysate a detergent to provide a high-salt-detergent lysate; and recovering said P450 from said lysate. The method provides yields of P450 proteins suitable for crystallization.